Currently Enrolling Studies

1	Recruiting	To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection	Clostridium Difficile Infection	Drug: ridinilazole Drug: vancomycin	Physicians Research Group Tempe, Arizona, United States Rajiv Parikh MD Tempe, Arizona, United States Arkansas Gastroenterology North Little Rock, Arkansas, United States (and 105 more…)
2	Recruiting	Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance	HIV-1-infection	Drug: Oral Lenacapavir Drug: Placebo oral tablet Drug: Subcutaneous Lenacapavir (and 2 more…)	Ruane Clinical Research Group Inc Los Angeles, California, United States Mills Clinical Research Los Angeles, California, United States Eisenhower Health Center at Rimrock Palm Springs, California, United States (and 30 more…)
3	Recruiting	Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With Other Antiretroviral Agents in People Living With HIV	HIV-1-infection	Drug: Oral Lenacapavir Drug: F/TAF Drug: Subcutaneous Lenacapavir (and 3 more…)	Alabama Medical Group, PC (Drug Shipment Address) Mobile, Alabama, United States Valleywise Community Health Center – McDowell Phoenix, Arizona, United States Pueblo Family Physicians Phoenix, Arizona, United States (and 54 more…)
4	Recruiting	Pharmacokinetic, Safety, and Efficacy of B/F/TAF in HIV-1 Infected, Virologically Suppressed, Pregnant Women in Their Second and Third Trimesters	HIV-1-infection	Drug: B/F/TAF	Miller Children’s & Women’s Hospital Long Beach Long Beach, California, United States Midway Immunology and Research Center Fort Pierce, Florida, United States University of South Florida Tampa, Florida, United States (and 8 more…)
5	Recruiting	Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults	HIV-1/HBV Co-Infection	Drug: B/F/TAF Drug: Placebo to match DTG Drug: Placebo to match F/TDF (and 3 more…)	Spectrum Medical Group Phoenix, Arizona, United States University of California Davis, One Community Health Sacramento, California, United States Yale University; School of Medicine New Haven, Connecticut, United States (and 83 more…)
6	Recruiting	Randomized, Double-blind, Efficacy, and Safety Study of Doravirine/Islatravir (DOR/ISL) in Treatment-naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)	HIV-1 Infection	Drug: DOR/ISL Drug: BIC/FTC/TAF Drug: Placebo to BIC/FTC/TAF Drug: Placebo to DOR/ISL	University of Alabama at Birmingham 1917 Research Clinic ( Site 5610) Birmingham, Alabama, United States Pueblo Family Physicians ( Site 5606) Phoenix, Arizona, United States Ruane Clinical Research Group, Inc. ( Site 5624) Los Angeles, California, United States (and 21 more…)
7	Recruiting	Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017))	HIV Infection	Drug: DOR/ISL	Georgetown University Hospital ( Site 1018) Washington, District of Columbia, United States Midway Immunology and Research ( Site 1030) Fort Pierce, Florida, United States Orlando Immunology Center ( Site 1007) Orlando, Florida, United States (and 43 more…)
8	Recruiting	Expanded Access Treatment Protocol: Remdesivir for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19) (GS-US-540-5821)	COVID-19	Drug: Remdesivir	Major Inclusion/Exclusion Criteria: Hospitalized with confirmed positive COVID-19 test 18 years or older On ventilator or tracheostomy
9	Not yet Recruiting	Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With CoronaVirus Induced Disease 2019 (COVID-19) and Pulmonary Distress	COVID-19	Drug: Ibrutinib	Major Inclusion/Exclusion Criteria: Hospitalized with confirmed positive COVID-19 test 18 years or older On ventilator Uncontrolled High Blood Pressure